123 related articles for article (PubMed ID: 30445232)
1. Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study.
Mejía M; Rodríguez-Leyva I; Cortés-Enríquez F; Chi-Ahumada E; Portales-Pérez DP; Macías-Islas MA; Jiménez-Capdeville ME
J Neurol Sci; 2019 Jan; 396():87-93. PubMed ID: 30445232
[TBL] [Abstract][Full Text] [Related]
2. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
[TBL] [Abstract][Full Text] [Related]
3. Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.
Rodi M; Dimisianos N; de Lastic AL; Sakellaraki P; Deraos G; Matsoukas J; Papathanasopoulos P; Mouzaki A
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571060
[TBL] [Abstract][Full Text] [Related]
4. [Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example Sema4D and CD72].
Danchenko IY; Baidina TV; Kuklina EM; Trushnikova TN; Nekrasova IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):63-71. PubMed ID: 31934990
[TBL] [Abstract][Full Text] [Related]
5. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Festoff BW; Li C; Woodhams B; Lynch S
J Neurol Sci; 2012 Dec; 323(1-2):61-5. PubMed ID: 22967748
[TBL] [Abstract][Full Text] [Related]
6. SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.
Malhotra S; Castilló J; Bustamante M; Vidal-Jordana A; Castro Z; Montalban X; Comabella M
Mult Scler; 2013 Apr; 19(5):524-31. PubMed ID: 22933622
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
[TBL] [Abstract][Full Text] [Related]
8. Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis.
Matsui M; Araya S; Wang HY; Matsushima K; Saida T
J Neurol; 2005 Aug; 252(8):908-15. PubMed ID: 15772738
[TBL] [Abstract][Full Text] [Related]
9. Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.
Romme Christensen J; Börnsen L; Hesse D; Krakauer M; Sørensen PS; Søndergaard HB; Sellebjerg F
J Neuroinflammation; 2012 Sep; 9():215. PubMed ID: 22978757
[TBL] [Abstract][Full Text] [Related]
10. Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes.
Alexander JS; Chervenak R; Weinstock-Guttman B; Tsunoda I; Ramanathan M; Martinez N; Omura S; Sato F; Chaitanya GV; Minagar A; McGee J; Jennings MH; Monceaux C; Becker F; Cvek U; Trutschl M; Zivadinov R
J Neurol Sci; 2015 Aug; 355(1-2):84-9. PubMed ID: 26073484
[TBL] [Abstract][Full Text] [Related]
11. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
[TBL] [Abstract][Full Text] [Related]
12. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis.
Frisullo G; Mirabella M; Angelucci F; Caggiula M; Morosetti R; Sancricca C; Patanella AK; Nociti V; Iorio R; Bianco A; Tomassini V; Pozzilli C; Tonali PA; Matarese G; Batocchi AP
J Neuroimmunol; 2007 Dec; 192(1-2):174-83. PubMed ID: 17904647
[TBL] [Abstract][Full Text] [Related]
13. Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients.
Bilge N; Simsek F; Yevgi R; Ceylan M; Askın S
J Neuroimmunol; 2020 Nov; 350():577432. PubMed ID: 33220655
[TBL] [Abstract][Full Text] [Related]
14. Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis.
Kim Y; Kim G; Shin HJ; Hyun JW; Kim SH; Lee E; Kim HJ
J Neuroinflammation; 2018 Oct; 15(1):300. PubMed ID: 30373595
[TBL] [Abstract][Full Text] [Related]
15. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
Szczuciński A; Kalinowska A; Losy J
Eur Neurol; 2007; 58(4):228-32. PubMed ID: 17827967
[TBL] [Abstract][Full Text] [Related]
16. Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
Tawfik TZ; Gad AH; Mehaney DA; El Nahrery E; Shehata HS; Hashem H; Ghaffar NFA; Shalaby N
J Neurol Sci; 2016 Oct; 369():36-38. PubMed ID: 27653861
[TBL] [Abstract][Full Text] [Related]
17. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.
Doppler K; Jentschke HM; Schulmeyer L; Vadasz D; Janzen A; Luster M; Höffken H; Mayer G; Brumberg J; Booij J; Musacchio T; Klebe S; Sittig-Wiegand E; Volkmann J; Sommer C; Oertel WH
Acta Neuropathol; 2017 Apr; 133(4):535-545. PubMed ID: 28180961
[TBL] [Abstract][Full Text] [Related]
18. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.
Frisullo G; Iorio R; Plantone D; Marti A; Nociti V; Patanella AK; Batocchi AP
Mult Scler; 2011 May; 17(5):556-66. PubMed ID: 21177324
[TBL] [Abstract][Full Text] [Related]
19. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
[TBL] [Abstract][Full Text] [Related]
20. CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study.
Belogurov A; Zakharov K; Lomakin Y; Surkov K; Avtushenko S; Kruglyakov P; Smirnov I; Makshakov G; Lockshin C; Gregoriadis G; Genkin D; Gabibov A; Evdoshenko E
Neurotherapeutics; 2016 Oct; 13(4):895-904. PubMed ID: 27324388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
